+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Pre Exposure Prophylaxis"

Pre-Exposure Prophylaxis Market - Global Forecast 2026-2032 - Product Thumbnail Image

Pre-Exposure Prophylaxis Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 197 Pages
  • Global
From
Long-acting PrEP Market - Global Forecast 2026-2032 - Product Thumbnail Image

Long-acting PrEP Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 188 Pages
  • Global
From
HIV Vaccines Market - Global Forecast 2026-2032 - Product Thumbnail Image

HIV Vaccines Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 181 Pages
  • Global
From
HIV Clinical Trials Market - Global Forecast 2026-2032 - Product Thumbnail Image

HIV Clinical Trials Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 187 Pages
  • Global
From
From
Anti-Retroviral Drugs Market - Global Forecast 2026-2032 - Product Thumbnail Image

Anti-Retroviral Drugs Market - Global Forecast 2026-2032

  • Report
  • January 2026
  • 194 Pages
  • Global
From
From
Human Immunodeficiency Virus Therapeutics Market Report 2026 - Product Thumbnail Image

Human Immunodeficiency Virus Therapeutics Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Integrase Inhibitors Market - Global Strategic Business Report - Product Thumbnail Image

Integrase Inhibitors Market - Global Strategic Business Report

  • Report
  • October 2026
  • 371 Pages
  • Global
From
Anti-Retroviral Drugs - Global Strategic Business Report - Product Thumbnail Image

Anti-Retroviral Drugs - Global Strategic Business Report

  • Report
  • October 2026
  • 280 Pages
  • Global
From
HIV Clinical Trials - Global Strategic Business Report - Product Thumbnail Image

HIV Clinical Trials - Global Strategic Business Report

  • Report
  • October 2026
  • 379 Pages
  • Global
From
HIV Drugs - Global Strategic Business Report - Product Thumbnail Image

HIV Drugs - Global Strategic Business Report

  • Report
  • October 2026
  • 295 Pages
  • Global
From
HIV or AIDS Diagnostics Market - Global Forecast 2026-2032 - Product Thumbnail Image

HIV or AIDS Diagnostics Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 193 Pages
  • Global
From
From
From
From
From
From
HIV Drugs and Injectables Market Report 2024-2034 - Product Thumbnail Image

HIV Drugs and Injectables Market Report 2024-2034

  • Report
  • July 2024
  • 288 Pages
  • Global
From
Loading Indicator

Pre Exposure Prophylaxis (PrEP) is a form of HIV prevention that involves taking a daily pill to reduce the risk of HIV infection. PrEP is a combination of two antiretroviral drugs, tenofovir and emtricitabine, which are used to treat HIV. PrEP is recommended for people who are at high risk of HIV infection, such as men who have sex with men, transgender women, and people who inject drugs. PrEP is highly effective in preventing HIV infection when taken as prescribed. PrEP is available in many countries around the world, and is becoming increasingly accessible. PrEP is typically prescribed by a healthcare provider and is available in both generic and branded forms. The cost of PrEP varies depending on the country and the type of drug prescribed. Several pharmaceutical companies are involved in the PrEP market, including Gilead Sciences, Mylan, and Teva Pharmaceuticals. Gilead Sciences is the largest manufacturer of PrEP drugs, with its branded drug Truvada being the most widely used PrEP drug. Mylan and Teva Pharmaceuticals also produce generic versions of PrEP drugs. Show Less Read more